{"id":"W4205735812","doi":"10.1182/blood-2018-99-114502","title":"Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Brentuximab vedotin; Refractory (planetary science); Oncology; Phases of clinical research; Clinical trial; Lymphoma; Surgery; Cancer; Hodgkin lymphoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001929824,0.0003791936,0.0007099413,0.0002029481,0.0002931262,0.0008465399,0.0004487147,0.0004608751,0.001290031],"category_scores_gemma":[0.001386521,0.0001967953,0.001145256,0.0002953513,0.0001870335,0.0004652789,0.0004392375,0.0008733077,0.0002027597],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005877082,"about_ca_system_score_gemma":0.0005690703,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001041888,"about_ca_topic_score_gemma":0.002904967,"domain_scores_codex":[0.9996118,0.0001811963,0.00003162511,0.00008068972,0.00004487301,0.00004980907],"domain_scores_gemma":[0.9991575,0.0001425634,0.0002415491,0.0001055107,0.00009505374,0.0002578027],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4294321,0.005939526,0.3898155,0.002083545,0.0101668,0.0005275577,0.0004490446,0.00277337,0.01335783,0.0004609425,0.01095326,0.1340406],"study_design_scores_gemma":[0.09765269,0.07704465,0.7965064,0.0004919763,0.008754945,0.0008951761,0.0002003524,0.002535734,0.002200058,0.0004634874,0.01316044,0.00009417935],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923531,0.003441873,0.000195598,0.00017396,0.00005290803,0.000371884,0.002461452,0.00001600457,0.000933283],"genre_scores_gemma":[0.9914409,0.0007394867,0.0004285373,0.0004739856,0.0001010386,0.0004233248,0.005931627,0.000006014903,0.0004550452],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001929824,"threshold_uncertainty_score":0.01020598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01650976570837826,"score_gpt":0.2847018162377192,"score_spread":0.2681920505293409,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}